ArticleCancer medicine2026
Impact of Underlying Liver Disease on the Risk and Prognostic Factors of Breast Cancer Liver Metastases: A Retrospective Multicenter Cohort Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectiveTo examine factors influencing breast cancer liver metastases (BCLM) and assess the impact of underlying liver diseases (nonalcoholic fatty liver and HBsAg infection) on BCLM development.
methodsPatients diagnosed with breast cancer at four affiliated hospitals in China between 2014 and 2024 were included. Logistic regression was used to identify factors associated with BCLM. Propensity score matching (PSM) and Kaplan-Meier analyses were performed to evaluate the prognostic impact of underlying liver diseases.
resultsA total of 3653 breast cancer patients were included, among whom 387 (11%) were identified with liver metastasis (LM). Factors including nonalcoholic fatty liver (NAFL) and HBsAg (hepatitis B surface antigen) infection were independently associated with a lower risk of BCLM (NAFL: p < 0.001; HBsAg: p = 0.011). Subsequent analysis stratified by the severity of NAFL indicated that mild NAFL was associated with a lower risk of BCLM, whereas moderate-to-severe NAFL was associated with a higher risk of BCLM (p = 0.01 and p = 0.02, respectively). Survival analysis showed that HBsAg infection was associated with significantly longer liver metastasis-free survival (LMS) and overall survival (OS) (both p < 0.01). Further survival analysis, stratified by the presence of NAFL, revealed that mild NAFL could prolong both LMS and OS, while moderate-to-severe NAFL not only shortened LMS, but also shortened OS after LM (OSLM), so that OS was significantly shortened (p < 0.01 for mild NAFL; p < 0.05 for LMS and p < 0.01 for OSLM and OS in moderate-to-severe NAFL). Furthermore, consistent results on OS and OSLM were obtained even after employing 1:1 PSM to account for other covariate interferences (both p < 0.01).
conclusionMild NAFL may be associated with reduced LM and improved prognosis, while moderate-to-severe NAFL appears to correlate with increased LM risk and worse clinical outcomes. Furthermore, HBsAg infection may be linked to suppressed LM and extended OS for patients with BCLM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.